COMBI-d: PFS and OS
a
Presented by: Keith T. Flaherty, MD
a
Intent-to-treat population;
b
Dabrafenib + placebo includes 26 patients who crossed over to combination arm; +, censored.
Overall Survival
212
175
138
104
84
69
57
7
0
211
187
143
111
96
86
76
13
0
Dabrafenib + Trametinib (n = 211)
Dabrafenib + Placebo (n = 212)
b
3-y OS, 44%
3-y OS, 32%
1.0
0.8
0.6
0.4
0.2
0.0
0
6
12
30
18
Months From Randomization
OS Probability
D+Pbo
D+T
Number at risk
2-y OS, 52%
2-y OS, 43%
24
36
42
48
Progression-Free Survival
212
110
67
41
29
11
7
1
0
211
137
84
69
54
45
31
0
1.0
0.8
0.6
0.4
0.2
0.0
0
Months From Randomization
PFS Probability
D+Pbo
D+T
Number at risk
6
12
30
18
24
36
42
48
3-y PFS, 22%
3-y PFS, 12%
2-y PFS, 30%
2-y PFS, 16%
Dabrafenib + Trametinib (n = 211)
Dabrafenib + Placebo (n = 212)
58% of D+T patients alive at
3 years still on D+T
NP4: 1606042435
